203 related articles for article (PubMed ID: 23307233)
1. Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure.
Yeo KR; Kenny JR; Rostami-Hodjegan A
Eur J Clin Pharmacol; 2013 Jun; 69(6):1311-20. PubMed ID: 23307233
[TBL] [Abstract][Full Text] [Related]
2. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.
Aquilante CL; Bushman LR; Knutsen SD; Burt LE; Rome LC; Kosmiski LA
Hum Genomics; 2008 Sep; 3(1):7-16. PubMed ID: 19129086
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel allelic variant of CYP2C8, CYP2C8*11, in Asian populations and its clinical effect on the rosiglitazone disposition in vivo.
Yeo CW; Lee SJ; Lee SS; Bae SK; Kim EY; Shon JH; Rhee BD; Shin JG
Drug Metab Dispos; 2011 Apr; 39(4):711-6. PubMed ID: 21245287
[TBL] [Abstract][Full Text] [Related]
4. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects.
Hruska MW; Amico JA; Langaee TY; Ferrell RE; Fitzgerald SM; Frye RF
Br J Clin Pharmacol; 2005 Jan; 59(1):70-9. PubMed ID: 15606443
[TBL] [Abstract][Full Text] [Related]
5. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.
Tornio A; Niemi M; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2008 Jan; 36(1):73-80. PubMed ID: 17913794
[TBL] [Abstract][Full Text] [Related]
6. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.
Pedersen RS; Damkier P; Brosen K
Br J Clin Pharmacol; 2006 Dec; 62(6):682-9. PubMed ID: 16856883
[TBL] [Abstract][Full Text] [Related]
7. The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.
Naik H; Wu JT; Palmer R; McLean L
Br J Clin Pharmacol; 2012 Aug; 74(2):327-35. PubMed ID: 22242967
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
Kirchheiner J; Thomas S; Bauer S; Tomalik-Scharte D; Hering U; Doroshyenko O; Jetter A; Stehle S; Tsahuridu M; Meineke I; Brockmöller J; Fuhr U
Clin Pharmacol Ther; 2006 Dec; 80(6):657-67. PubMed ID: 17178266
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.
Hertz DL; Walko CM; Bridges AS; Hull JH; Herendeen J; Rollins K; Watkins PB; Dees EC
Br J Clin Pharmacol; 2012 Jul; 74(1):197-200. PubMed ID: 22680343
[TBL] [Abstract][Full Text] [Related]
10. Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.
Doki K; Darwich AS; Achour B; Tornio A; Backman JT; Rostami-Hodjegan A
Br J Clin Pharmacol; 2018 May; 84(5):972-986. PubMed ID: 29381228
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
Jaakkola T; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):44-51. PubMed ID: 16867170
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers.
Aquilante CL; Wempe MF; Spencer SH; Kosmiski LA; Predhomme JA; Sidhom MS
Pharmacotherapy; 2013 Sep; 33(9):1000-7. PubMed ID: 23712614
[TBL] [Abstract][Full Text] [Related]
13. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
[TBL] [Abstract][Full Text] [Related]
14. Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects.
Kim KA; Park PW; Kim HK; Ha JM; Park JY
J Clin Pharmacol; 2005 Aug; 45(8):941-6. PubMed ID: 16027405
[TBL] [Abstract][Full Text] [Related]
15. Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.
Aquilante CL; Kosmiski LA; Bourne DW; Bushman LR; Daily EB; Hammond KP; Hopley CW; Kadam RS; Kanack AT; Kompella UB; Le M; Predhomme JA; Rower JE; Sidhom MS
Br J Clin Pharmacol; 2013 Jan; 75(1):217-26. PubMed ID: 22625877
[TBL] [Abstract][Full Text] [Related]
16. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.
Niemi M; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2004 Sep; 76(3):239-49. PubMed ID: 15371985
[TBL] [Abstract][Full Text] [Related]
17. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.
Baldwin SJ; Clarke SE; Chenery RJ
Br J Clin Pharmacol; 1999 Sep; 48(3):424-32. PubMed ID: 10510156
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
Derks M; Fowler S; Kuhlmann O
Curr Med Res Opin; 2009 Apr; 25(4):891-902. PubMed ID: 19245299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
